This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Ramadan constitutes the annual fasting period for over a billion Muslims worldwide, during which people totally abstain from food and drink from sunrise until sunset. During Ramadan, the lifestyle of these fasting people changes temporarily, affecting their eating pattern, sleeping periods, physical activity, and smoking habits [1]; these alterations may in turn affect the health status of patients suffering from cardiovascular diseases and its risk factors (hypertension, diabetes, dyslipidemia, and imbalanced autonomic nervous activity) [2].
One of the highly prevalent cardiovascular disease risk factors is hypertension, which occurs between 18% and 27% worldwide depending on the region [3]. Hypertensive heart disease is considered a leading risk for early deaths and disability [4] and, according to the global health estimates, is ranked among the top 20 causes of mortality worldwide, accounting for 1.6% of total deaths in 2016 [5].
Limited number of studies (5 research manuscripts as for April 2020) demonstrated the effect of Ramadan fasting on blood pressure, and cardiovascular parameters in hypertensive patients, who adhered to their antihypertensive medications [6–10]. Previous research was diverse in terms of hypertension grade of subjects that ranged from pre-hypertensive state [11] to grade 3 hypertension [7]. In addition, different inclusion criteria were applied (such as diabetes, cardiac hypertrophy, sinus arrhythmia, renal disease, etc.), and different fasting durations were studied (from 12 hours [7] to 16 hours [10]). Of note, some cardiac outcomes (such as lipid panel [8] and autonomic nervous system [10]) were only evaluated once with a relatively low sample size.
Previous review studies concur that Ramadan fasting has no significant effect on blood pressure measurements of hypertensive subjects [12, 13] and claim that fasting may be a safe practice for patients with controlled hypertension [2]. On the other hand, conflicting results were reported for the variation in body weight [6, 7, 9], as well as in heart rate [9, 10], of hypertensive patients during Ramadan fasting.
Additionally, few studies described an improvement in lipid panel, as evidenced by a significant increase in high density lipoproteins (HDL) and decrease in triglycerides and low density lipoproteins (LDL); also an enhancement in oxidative stress profile was observed, reported as an increase in the antioxidant glutathione and a decrease in the reactive compound malondialdehyde, an oxidative stress biomarker [8].
In a recent study, Mzoughi et al. also assessed the autonomic nervous activity during Ramadan and claimed decreased heart rate variability and enhanced sympathetic activity among hypertensive patients with sinus rhythm, who varied significantly in terms of lifestyle characteristics [10].
To our knowledge, this is the first study to collectively address multiple cardiac health parameters among the same group of hypertensive subjects with homogenous characteristics during Ramadan fasting. This research aims to evaluate the intraday and interday effect of fasting on cardiac health at the level of the autonomic nervous system activity (heart rate variability), lipid profile, blood pressure, and body composition among patients with controlled hypertension.
2. Materials and Methods
2.1. Study Design
In this observational prospective cohort, participants were followed for 24 h under two conditions: fasting state during the last two weeks of Ramadan, and nonfasting state one month after Ramadan. Participants were instructed to follow their regular medication posology and their routine activities in both monitoring phases.
2.2. Study Participants
The study was done according to the Declaration of Helsinki, with an IRB approval granted from Rafic Hariri University Hospital (Beirut, Lebanon). All participants signed an informed consent form prior to their enrollment. Participants were considered eligible if over 18 years old, with controlled hypertension by the use of antihypertensive medications (SBP ≤ 129 mmHg and DBP < 80 mmHg) [14], and willing to voluntarily fast for at least 15 days of Ramadan. Patients who had chronic CVD, patients who underwent surgeries in the past two years, and pregnant women were excluded from the study.
2.3. Data Collection
Data was collected by means of individualized visits, preserving the natural setting for participants in which they followed their routine activities.
2.3.1. Anthropometric Measurements
Morning baseline measurements were recorded for the body composition of participants at each visit. The body height and waist and hip circumferences (cm) were measured by a regular meter. BF511 body composition monitor (Omron Healthcare, Lebanon) was used to evaluate the body weight (kg), body mass index (BMI) (kg/m2), total body fat (%), visceral fat level, skeletal muscle (%), and resting metabolism (kcal).
2.3.2. Blood Pressure Measurement
Blood pressure was measured using an Omron M3 HEM-7131-E blood pressure monitor (Omron Healthcare, Lebanon). Measurements were recorded at four time points (during/after Ramadan) after a 10–15 min rest in the sitting posture: (1) baseline morning measurement, (2) one hour before breaking fast/before having lunch, (3) one hour after breaking fast/after having lunch, and (4) terminal morning measurement.
2.3.3. Blood Test Analysis
Blood samples for all participants were collected at the end of each phase and analyzed for lipid profile (triglyceride, total cholesterol, LDL, HDL, non-HDL (mg/dl)) and blood glucose levels (mg/dl).
2.3.4. Cardiac Monitoring and Heart Rate Variability Analysis
Participants were monitored for ECG over 24 h in fasting and nonfasting conditions using validated and medical CE certified Bittium Faros cardiac monitoring device 360° (Bittium Biosignals, Kuopio, Finland) at a sampling rate of 250 Hz; monitoring was done through 1-channel, 3-electrode cable set, attached to the skin by Ambu® WhiteSensor WS adhesive electrodes (Ambu®, Copenhagen, Denmark). Heart rate variability (HRV) was then analyzed using HRV Scanner Professional software V. 3.05.13 (Bittium Biosignals, Kuopio, Finland). Short-term HRV was analyzed over 5 min interval at 3 times points matching blood pressure measurements while participant is at rest (i.e., (1) one hour before breaking fast/before having lunch, (2) one hour after breaking fast/after having lunch, and (3) terminal morning measurement).
2.3.5. Questionnaire
A structured questionnaire was filled during and after Ramadan regarding the lifestyle and monitoring days’ activities of participants. The questionnaire was designed and piloted by the researchers prior to implementation of the study, after which a final version was developed. It covered baseline demographics, medical history, dosing regimens of administered medications during and after Ramadan, smoking status, physical activities, meal consumption, and sleeping pattern.
2.4. Statistical Analysis
Statistical analysis was done using IBM SPSS statistics V.20.00. Results are presented as mean ± standard error mean (SEM), and statistical significance was considered at
3. Results
3.1. Population Determinants
The study included 58 participants (30 male, 28 female) with a mean age of 54.3 ± 11.5 years. Baseline characteristics of participants are illustrated in Table 1; the majority were married (84.5%) and employed (62.1%). Almost all participants consumed caffeine on a daily basis, with 44.9% having 3 or more cups of caffeinated drinks per day. Most of the participants presented sedentary lifestyle (79.3%) and were almost equally distributed between smokers and nonsmokers.
Table 1
Characteristics of included participants in terms of demographics, lifestyle, and disease history.
Parameter | Frequency (percentage) | |
Demographics | Gender | |
Male | 30 (51.7) | |
Female | 28 (48.3) | |
Age (years ± SD) | 54.27 ± 11.48 | |
Marital status | ||
Single | 2 (3.4) | |
Married | 49 (84.5) | |
Widowed | 7 (12.1) | |
Highest obtained degree | ||
None | 1 (1.7) | |
Middle school | 20 (34.5) | |
High school | 14 (24.1) | |
University | 23 (39.7) | |
Occupational status | ||
Unemployed | 21 (36.2) | |
Employed | 36 (62.1) | |
Retired | 1 (1.7) | |
Lifestyle | Cups of caffeinated drinks per day | |
None | 1 (1.7) | |
1-2 cups | 26 (44.8) | |
3-4 cups | 19 (32.8) | |
≥5 cups | 7 (12.1) | |
Rarely | 5 (8.6) | |
Physical activity | ||
None | 46 (79.3) | |
Jogging | 5 (8.6) | |
Weight lifting | 1 (1.7) | |
Gym | 1 (1.7) | |
Football | 1 (1.7) | |
Aerobics | 1 (1.7) | |
Combined activity | 3 (5.1) | |
Smoking habits | ||
Nonsmokers | ||
Never smoked | 20 (34.5) | |
Ex-smoker <1 y ago | 1 (1.7) | |
Ex-smoker >1 y ago | 9 (15.5) | |
Smokers | ||
Cigarettes | 8 (13.8) | |
Hookah | 19 (32.8) | |
Both | 1 (1.7) | |
Disease history | Hypertension | |
≤1 year ago | 4 (6.9) | |
1-2 years ago | 8 (13.8) | |
3-4 years ago | 9 (15.5) | |
≥5 years ago | 37 (63.8) | |
Other diseases | ||
Hyperlipidemia | 38 (65.5) | |
Diabetes | 14 (24.1) | |
Thyroid disease | 9 (15.5) | |
Antihypertensive medication | Antihypertensive therapy | |
No therapy | 2 (3.44) | |
Mono-therapy | 19 (32.75) | |
Combination therapy | ||
2 drugs | 22 (37.93) | |
≥3 drugs | 15 (25.86) | |
Class of antihypertensive drugs | ||
Beta blocker | 26 (44.8) | |
Angiotensin converting enzyme inhibitor | 14 (24.1) | |
Angiotensin II receptor blocker | 24 (41.4) | |
Calcium channel blocker | 21 (36.2) | |
Diuretics | 23 (39.7) | |
Tau/dosing frequency | ||
12 hours/twice daily | 10 (17.2) | |
24 hours/once daily | 42 (72.4) | |
When needed | 4 (6.9) |
Patients varied in terms of hypertension condition duration, with 63.8% being diagnosed with hypertension for more than 5 years, and a minority (6.9%) diagnosed during the last year. More than half of the participants reported having dyslipidemia (65.5%), and almost a quarter reported having diabetes (24.1%). Patients followed either a mono-therapy for hypertension (32.8%), or combinational therapy of 2 or 3 drugs (63.8%). Therapies included different classes of antihypertensive drugs, with beta blocker and angiotensin II receptor blockers being the most utilized (44.8% and 41.4%, respectively).
3.2. Effect of Ramadan Fasting on Body Composition
Body composition parameters were clustered per gender (Table 2). Females did not present any significant change in body composition in response to fasting. Males presented significantly lower body weight (mean difference 1.07 kg,
Table 2
Anthropometric measurements during and after Ramadan.
Male | Female | |||||
During Ramadan | After Ramadan | During Ramadan | After Ramadan | |||
Height (cm) | 174.21 ± 1.62 | 157.43 ± 1.32 | ||||
Body weight (kg) | 100.39 ± 3.88 | 101.32 ± 3.96 | 0.045 | 82.26 ± 2.23 | 81.95 ± 2.28 | 0.247 |
BMI (kg/m2) | 32.54 ± 1.09 | 32.91 ± 1.14 | 0.037 | 33.26 ± 0.93 | 33.22 ± 0.96 | 0.786 |
Body fat (%) | 31.78 ± 1.48 | 32.08 ± 1.45 | 0.544 | 47.69 ± 1.00 | 47.21 ± 1.13 | 0.398 |
Skeletal muscle (%) | 30.88 ± 0.76 | 30.71 ± 0.72 | 0.575 | 22.47 ± 0.45 | 22.75 ± 0.52 | 0.442 |
Resting metabolism (kcal) | 1961.25 ± 52.19 | 1972.00 ± 53.22 | 0.099 | 1500.28 ± 25.36 | 1496.96 ± 25.14 | 0.307 |
Visceral fat level | 16.62 ± 1.12 | 17.00 ± 1.13 | 0.09 | 11.78 ± 0.60 | 11.53 ± 0.61 | 0.090 |
Waist circumference (cm) | 113.85 ± 3.75 | 115.81 ± 2.73 | 0.384 | 106.10 ± 1.96 | 107.62 ± 3.25 | 0.609 |
Hip circumference (cm) | 113.74 ± 1.93 | 115.05 ± 1.99 | 0.023 | 116.25 ± 1.81 | 115.26 ± 1.81 | 0.091 |
Waist-hip ratio | 0.99 ± 0.02 | 1.00 ± 0.01 | 0.768 | 0.91 ± 0.01 | 0.93 ± 0.02 | 0.369 |
Values presented as mean ± SEM.
3.3. Effect of Ramadan Fasting on Lipid Profile and Blood Glucose Levels
Lipid profile and blood glucose levels are reported in Table 3. Mean triglyceride levels were elevated (>160 mg/dl presented by 48.27% of patients during and after Ramadan), and mean HDL cholesterol levels were normal within the lower borderline, yet yielding a high total cholesterol to HDL cholesterol ratio (>5 in 37.93% and 36.21% of subjects during and after Ramadan, respectively). Fasting did not significantly alter any of the lipid panel parameters (
Table 3
Lipid profile and glycemic levels among participants during and after Ramadan.
During Ramadan | After Ramadan | Normal values | ||
Triglyceride (mg/dl) | 261.71 ± 46.54 | 223.54 ± 26.92 | 0.169 | 40–160 |
Total cholesterol (mg/dl) | 189.29 ± 7.15 | 184.21 ± 7.04 | 0.288 | 135–220 |
HDL cholesterol (mg/dl) | 39.07 ± 1.42 | 39.40 ± 1.37 | 0.569 | 35–55 |
LDL cholesterol (mg/dl) | 120.22 ± 7.36 | 114.80 ± 7.05 | 0.253 | Optimal recommended <130 |
Diabetics recommended <100 | ||||
LDL/HDL ratio | 3.49 ± 0.31 | 3.25 ± 0.29 | 0.110 | 0–3.6 |
Total cholesterol/HDL cholesterol ratio | 5.33 ± 0.34 | 5.08 ± 0.32 | 0.113 | 0–5 |
Non-HDL cholesterol (mg/dl) | 150.22 ± 7.36 | 144.82 ± 7.05 | 0.254 | Reference value <160 |
For subjects at high risk of CVD <130 | ||||
For subjects at very high risk of CVD <100 | ||||
Blood glucose (mg/dl) | 121.24 ± 36.12 | 114.59 ± 39.20 | 0.023 | 70–120 |
Values presented as mean ± SEM. Normal values adapted from Saint Joseph Medical Center reports.
3.4. Effect of Ramadan Fasting on Blood Pressure Variation
Subjects presented normotensive profile in fasting and nonfasting conditions. SBP and DBP were comparable throughout a fasting and nonfasting day; also, no significant difference was observed between fasting and nonfasting condition per measurement time point (Table 4,
Table 4
Blood pressure variation in fasting and nonfasting conditions.
During Ramadan | After Ramadan | ||
Systolic blood pressure (mmHg) | |||
Morning (baseline) | 128.48 ± 2.72 | 126.90 ± 1.83 | 0.362 |
Afternoon | 125.16 ± 2.15 | 124.61 ± 2.21 | 0.438 |
Evening | 127.72 ± 2.17 | 123.64 ± 2.09 | 0.103 |
Morning (end) | 126.36 ± 2.12 | 126.33 ± 1.71 | 0.880 |
0.750 | 0.615 | ||
Diastolic blood pressure (mmHg) | |||
Morning (baseline) | 86.36 ± 1.94 | 87.43 ± 2.20 | 0.816 |
Afternoon | 82.68 ± 1.64 | 85.23 ± 2.03 | 0.264 |
Evening | 80.38 ± 1.51 | 81.98 ± 1.71 | 0.213 |
Morning (end) | 84.03 ± 1.33 | 83.64 ± 1.52 | 0.810 |
0.076 | 0.202 |
Values presented as mean ± SEM.
3.5. Effect of Ramadan Fasting on Heart Rate Variability
Heart rate variability parameters measured at three time points per monitoring day are reported in Table 5. During Ramadan, morning and afternoon periods were comparable and showed significantly higher RR interval, SDNN, and SD2, and lower stress index versus the evening period of the same day (Figures 1(a), 1(b), 1(d), and 1(f);
Table 5
Heart rate variability analysis during and after Ramadan.
Afternoon | Evening | Morning | |||||||||
During Ramadan | After Ramadan | During Ramadan | After Ramadan | During Ramadan | After Ramadan | During Ramadan | After Ramadan | ||||
RR interval-derived parameters | |||||||||||
Mean RR interval (ms) | 749.96 ± 17.96 | 768.74 ± 14.92 | 0.092 | 707.37 ± 18.81 | 754.51 ± 13.44 | 0.009 | 817.68 ± 15.37 | 798.14 ± 15.02 | 0.181 | <0.0001 | 0.008 |
SDNN (ms) | 58.62 ± 5.24 | 44.44 ± 3.55 | 0.013 | 46.23 ± 5.95 | 40.52 ± 3.38 | 0.574 | 61.32 ± 4.39 | 53.36 ± 4.49 | 0.082 | 0.011 | 0.006 |
PNN50 (%) | 9.43 ± 2.40 | 8.14 ± 1.84 | 0.704 | 7.02 ± 2.23 | 6.35 ± 1.72 | 0.817 | 10.16 ± 2.44 | 9.87 ± 2.33 | 0.711 | 0.274 | 0.049 |
RMSSD (ms) | 40.14 ± 7.47 | 31.83 ± 5.01 | 0.349 | 32.37 ± 7.68 | 27.96 ± 3.97 | 0.805 | 34.72 ± 5.13 | 35.56 ± 5.56 | 0.984 | 0.394 | 0.204 |
SD1 (ms) | 28.38 ± 5.28 | 22.51 ± 3.54 | 0.348 | 22.89 ± 5.43 | 19.77 ± 2.81 | 0.805 | 24.55 ± 3.63 | 25.14 ± 3.93 | 0.984 | 0.394 | 0.204 |
SD2 (ms) | 75.17 ± 5.86 | 57.02 ± 4.03 | 0.006 | 59.30 ± 6.74 | 52.66 ± 4.16 | 0.565 | 81.32 ± 5.54 | 69.43 ± 5.41 | 0.059 | 0.003 | 0.005 |
SD2/SD1 | 4.68 ± 0.34 | 3.53 ± 0.23 | 0.001 | 4.51 ± 0.32 | 3.52 ± 0.25 | 0.009 | 4.94 ± 0.40 | 4.03 ± 0.29 | 0.086 | 0.518 | 0.148 |
Stress index (pts.) | 279.13 ± 32.42 | 350.43 ± 44.66 | 0.032 | 445.69 ± 45.62 | 347.31 ± 35.74 | 0.07 | 231.33 ± 25.99 | 261.68 ± 30.99 | 0.429 | <0.0001 | 0.014 |
Parameters spectral analysis | |||||||||||
Rel. power HF band (%) | 16.88 ± 2.60 | 16.64 ± 2.14 | 0.918 | 14.47 ± 2.23 | 15.53 ± 1.83 | 0.762 | 14.35 ± 1.86 | 19.82 ± 2.82 | 0.05 | 0.460 | 0.155 |
Rel. Power LF band (%) | 27.38 ± 1.88 | 34.73 ± 2.12 | 0.003 | 30.03 ± 1.64 | 35.55 ± 1.97 | 0.059 | 26.52 ± 1.61 | 29.23 ± 2.26 | 0.290 | 0.268 | 0.070 |
LF/HF ratio | 4.87 ± 0.83 | 3.41 ± 0.32 | 0.053 | 4.93 ± 0.59 | 4.15 ± 0.47 | 0.218 | 4.22 ± 0.62 | 4.54 ± 0.77 | 0.764 | 0.651 | 0.213 |
Rhythmisation degree | 7.10 ± 0.62 | 6.76 ± 0.61 | 0.464 | 6.00 ± 0.76 | 5.98 ± 0.46 | 0.165 | 6.37 ± 0.51 | 6.50 ± 0.48 | 0.710 | 0.260 | 0.266 |
HF band (0.150–0.400 Hz); LF band (0.040–0.150 Hz); VLF band (0.003–0.040 Hz); ULF band (0.0001–0.0030 Hz). Values presented as mean ± SEM.
[figures omitted; refer to PDF]
Upon comparing the same time point in two different conditions, HRV during morning period was similar in fasting and nonfasting condition. In the afternoon, fasting significantly reduced HRV and presented significantly higher SDNN, SD2, and SD2/SD1 ratio, and lower stress index and LF component (Figures 1(b), 1(d), 1(e), and 1(f);
4. Discussion
This research illustrates the effect of Ramadan fasting on the cardiac health of patients with hypertension, treated with different combinations of antihypertensive medications. Fasting did not affect body composition, lipid panel parameters, or blood pressure of hypertensive subjects; males only presented lower body weight and hip circumference during Ramadan. Blood glucose was significantly higher during Ramadan. Of note, fasting significantly increased HRV during the afternoon period.
The patients presented several CVD risk factors, including obesity and unfavorable body composition as shown by high levels of total and visceral fat versus the low percentage of skeletal muscle, and accompanied with very high BMI. Despite this unfavorable profile, body composition did not show any significant change in response to fasting, even though fasting significantly reduced BMI of males exclusively. Although fasting was shown to reduce the body weight and ameliorate the body composition of normotensive healthy adults [15, 16], results of previous studies regarding hypertensive subjects remain controversial. Two studies reported no significant change in body weight of hypertensive subjects [7, 9], which is consistent with our results for the whole group (
Dyslipidemia and high blood glucose levels are also considerable CVD risk factors. Our results revealed no significant effect on any lipid profile parameters, similar to that observed during and after Ramadan among patients with moderate hypertension on 2 or less antihypertensive drugs, and having a similar lipid profile to our results [8]. However, Al-Shafei reported that fasting induced a drop in LDL and an increase in HDL when compared to before the Ramadan period, which was maintained 6 weeks post-Ramadan, unlike the reversible drop in triglycerides [8]. The enhancement in lipid panel parameters as a function of fasting, observed by Al-Shafei, agrees with the favorable results reported among healthy population [17, 18]. Despite the fact that only 24% of patients reported having diabetes, fasting blood glucose appeared within the upper bound limits, which were significantly higher during Ramadan; this may be explained by the carbohydrate-rich meals consumed during Ramadan, and shorter overnight fasting hours prior to blood sample collection due to the sohour meal, a light meal consumed before sunrise during Ramadan. Further studies should investigate fasting effect on the biochemical profile to better understand the confounding factors affecting its variations.
Patients adhered to their antihypertensive medication posology (dose and frequency) during Ramadan and presented well-controlled blood pressure levels, lying within the normal recommended values [14], which tended to decrease between the morning and evening phases, and were comparable to nonfasting day. These results are consistent with previous findings that found no significant change in blood pressure levels during and after Ramadan [7, 9], and comparable to those reported before and during Ramadan [6, 9]. This is opposite to the fasting-induced decrease in blood pressure levels observed among patients with SBP 150–180 mmHg and/or DBP 95–120 mmHg [8]; despite the reduction reported by Al-Shafei [8], SBP and DBP did not reach normal recommended levels and were not controlled by use of 2 or less antihypertensive medications.
To our knowledge, this is the first study to report intraday variation of HRV among hypertensive patients in fasting state. Only one previous study addressed HRV among hypertensive subjects during Ramadan, but was limited to interday variation during and after Ramadan [10]. Mzoughi et al. observed a decrease in HRV, as evidenced by lower SDNN and SDANN (representative of whole HRV), and a further enhancement in the sympathetic nervous system upon fasting among hypertensive subjects suffering from sinus rhythm when compared to after the Ramadan period [10]. Mzoughi et al. study was done on a relatively low number of subjects (n = 20), who presented diverse characteristics in terms of smoking habits, antihypertensive medication classes, and combination therapies, and 20% presenting cardiac hypertrophy, which could be confounding factors. On the contrary, our results revealed an increase in HRV, and thereby a lower cardiac stress, only during the afternoon period during Ramadan, i.e., after prolonged fasting hours, compared to nonfasting day after Ramadan. Our results are similar to those reported among healthy individuals with sinus rhythm, who presented higher HRV during Ramadan compared to the first week after Ramadan ended [19]. HRV in the morning and evening periods were comparable during and after Ramadan, with the evening period during Ramadan showing only higher heart rate and SD2/SD1 ratio, which may be suggestive of slight increase in sympathetic nervous activity without affecting the overall HRV changes.
On the other hand, intraday analysis revealed that evening period showed lower HRV as evidenced by lower SDNN (sympathetic nervous system indicator) and SD2 (long term HRV marker) and higher stress levels compared to morning and afternoon period during Ramadan, and only to morning period after Ramadan. Our results during Ramadan are comparable to the circadian HRV changes observed among healthy female adults, who fasted for similar duration (16 hours) [20]. This may imply that, in nonfasting condition, there is a tendency to gradual decrease in HRV from the morning till the evening time as a result of food ingestion all day and metabolic activity needs, while upon fasting during Ramadan, the decrease in HRV is delayed until the evening period upon breaking fast and initiating the metabolic activities of the body after long hours of food deprivation. Further research should investigate the autonomic nervous activity of hypertensive subjects in response to Ramadan fasting to better describe the induced changes and elaborate the underlying mechanism behind changes in sympathetic and parasympathetic activities.
Overall, this study presents a novel finding regarding the intraday variations of the autonomic nervous activity as function of fasting. However, it lacks measurement before Ramadan, which may have been beneficial for analyzing fasting effect on lipid profile and blood glucose variations. Also, subjects were diverse in terms of antihypertensive medication combinations, which restricted a possible stratification of patients according to drug classes, knowing that beta blockers and calcium channel blockers have negative inotropic effects.
5. Conclusions
In conclusion, the present study provides evidence for lower cardiac stress upon prolonged hours of intermittent fasting, with controlled blood pressure levels during Ramadan fasting. This implies that Ramadan fasting may be a risk-free practice for patients adhering to their antihypertensive medication. Nonetheless, hypertensive patients are prone to developing further CVD by presenting a dyslipidemia profile, high blood glucose levels, and an unfavorable body composition, which were unaltered upon fasting, yet need further management to avoid undesired sudden cardiac-related events in fasting and nonfasting conditions.
This work may be complemented by including a larger sample size that allows for stratification of the results based on antihypertensive medication classes, and to study the interaction of possible confounding factors such as smoking and physical activity.
Acknowledgments
This work was funded by the Lebanese University grant to MK and RK. The authors thank Dr. George W. Booz (University of Mississippi Medical Center, Jackson, MS, USA) for his critical reading of the manuscript.
[1] A. Norouzy, M. Salehi, E. Philippou, "Effect of fasting in Ramadan on body composition and nutritional intake: a prospective study," Journal of Human Nutrition and Dietetics, vol. 26, pp. 97-104, DOI: 10.1111/jhn.12042, 2013.
[2] I. Salim, J. Al Suwaidi, W. Ghadban, H. Alkilani, A. M. Salam, "Impact of religious Ramadan fasting on cardiovascular disease: a systematic review of the literature," Current Medical Research and Opinion, vol. 29 no. 4, pp. 343-354, DOI: 10.1185/03007995.2013.774270, 2013.
[3] WHO, Hypertension, 2019. https://www.who.int/news-room/fact-sheets/detail/hypertension
[4] Institute of Health Metrix and Evaluations (IHME), Findings from the Global Burden of Disease Study 2017, 2018.
[5] WHO, Global Health Estimates, Summary Tables: Deaths by Cause, Age and Sex, by World Bank Income Group, 2000–2015, 2016. https://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html
[6] G. Perk, J. Ghanem, S. Aamar, D. Ben-Ishay, M. Bursztyn, "The effect of the fast of Ramadan on ambulatory blood pressure in treated hypertensives," Journal of Human Hypertension, vol. 15 no. 10, pp. 723-725, DOI: 10.1038/sj.jhh.1001262, 2001.
[7] E. Ural, G. Kozdag, T. Kilic, "The effect of Ramadan fasting on ambulatory blood pressure in hypertensive patients using combination drug therapy," Journal of Human Hypertension, vol. 22 no. 3, pp. 208-210, DOI: 10.1038/sj.jhh.1002296, 2008.
[8] A. I. M. Al-Shafei, "Ramadan fasting ameliorates arterial pulse pressure and lipid profile, and alleviates oxidative stress in hypertensive patients," Blood Pressure, vol. 23 no. 3, pp. 160-167, DOI: 10.3109/08037051.2013.836808, 2014.
[9] A. Norouzy, M. Hasanzade, A. Hosein, "Trend of blood pressure in hypertensive and normotensive volunteers during Ramadan fasting," Blood Pressure Monitering, vol. 22, pp. 253-257, DOI: 10.1097/MBP.0000000000000272, 2017.
[10] K. Mzoughi, I. Zairi, M. Jabeur, S. Kraiem, "The effects of fasting on heart rate variability in hypertensive patients," Clinical and Experimental Hypertension, vol. 40 no. 8, pp. 793-796, DOI: 10.1080/10641963.2018.1433194, 2018.
[11] Y. Erdem, G. Özkan, Ş. Ulusoy, "The effect of intermittent fasting on blood pressure variability in patients with newly diagnosed hypertension or prehypertension," Journal of the American Society of Hypertension, vol. 12 no. 1, pp. 42-49, DOI: 10.1016/j.jash.2017.11.008, 2018.
[12] H. Chamsi-Pasha, M. Chamsi-Pasha, "The cardiac patient in Ramadan," Avicenna Journal of Medicine, vol. 6 no. 2, pp. 33-38, DOI: 10.4103/2231-0770.179547, 2016.
[13] H. Chamsi-Pasha, W. H. Ahmed, K. F. Al-shaibi, "The cardiac patient during Ramadan and Hajj," Journal of the Saudi Heart Association, vol. 26 no. 4, pp. 212-215, DOI: 10.1016/j.jsha.2014.04.002, 2014.
[14] American Heart Association, Understanding Blood Pressure Readings, 2017. https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings
[15] H. Fernando, J. Zibellini, R. Harris, R. Seimon, A. Sainsbury, "Effect of Ramadan fasting on weight and body composition in healthy non-athlete adults: a systematic review and meta-analysis," Nutrients, vol. 11 no. 2,DOI: 10.3390/nu11020478, 2019.
[16] V. Ziaee, M. Razaei, Z. Ahmadinejad, "The changes of metabolic profile and weight during Ramadan fasting," Singapore Medical Journal, vol. 47, pp. 409-414, 2006.
[17] S. A. Saleh, T. A. El-Kemery, K. A. Farrag, "Ramadan fasting: relation to atherogenic risk among obese muslims," Journal of the Egyptian Public Health Association, vol. 79, pp. 461-483, 2004.
[18] A. Adlouni, N. Ghalim, A. Benslimane, J. M. Lecerf, R. Saïle, "Fasting during Ramadan induces a marked increase in high-density lipoprotein cholesterol and decrease in low-density lipoprotein cholesterol," Annals of Nutrition and Metabolism, vol. 41 no. 4, pp. 242-249, DOI: 10.1159/000177999, 1997.
[19] M. Cansel, H. Tasolar, J. Yagmur, "The effects of Ramadan fasting on heart rate variability in healthy individuals: a prospective study," Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology, vol. 14 no. 5, pp. 413-416, DOI: 10.5152/akd.2014.5108, 2014.
[20] S. Hammoud, R. Mourad, R. Karam, I. Saad, B. J. F. van den Bemt, M. Kurdi, "Effect of Ramadan fasting on heart rate variability as a measure of cardiac stress in a lebanese cohort," European Journal of Clinical Nutrition, vol. 74 no. 8, pp. 1237-1239, DOI: 10.1038/s41430-020-0562-2, 2020.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2021 Sabah Hammoud et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0/
Abstract
Background. Conflicting results are reported on the effect of Ramadan fasting on the cardiovascular health of patients with hypertension, a highly prevalent cardiovascular disease risk factor. This research aimed to evaluate the impact of fasting on cardiac health and heart rate variability (as a measure of cardiac stress) of hypertensive patients. Methods. Patients with controlled hypertension were followed in a prospective cohort during and after Ramadan. Lipid panel and blood glucose were measured at the end of each phase. Blood pressure and heart rate variability were monitored in the morning, afternoon, and evening of each follow-up day. Results. The study included 58 subjects (mean age: 54 ± 11.5 years, 52% male). Fasting did not affect body composition, lipid panel parameters, and blood pressure of hypertensive subjects; males only presented lower body weight and hip circumference during Ramadan. Blood glucose was significantly higher during Ramadan. Fasting significantly increased HRV during the afternoon period. Conclusions. Ramadan intermittent fasting reduces cardiac stress among hypertensive patients controlled by and adherent to hypertensive medication, without affecting their hypertensive state.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Laboratory of Experimental and Clinical Pharmacology, Faculty of Sciences, Section 1, Lebanese University, Rafic Hariri Educational Campus, Hadat, Lebanon; Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands
2 Laboratory of Experimental and Clinical Pharmacology, Faculty of Sciences, Section 1, Lebanese University, Rafic Hariri Educational Campus, Hadat, Lebanon
3 Laboratory of Experimental and Clinical Pharmacology, Faculty of Sciences, Section 1, Lebanese University, Rafic Hariri Educational Campus, Hadat, Lebanon; Department of Cardiology, Rafic Hariri University Hospital, Beirut, Lebanon
4 Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands; Department of Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands; Department of Pharmacy, University Medical Center Maastricht, Maastricht, Netherlands